Table 4

Number of events and mean drug consumption per patient at the three months follow up

Item	Dalteparin (n=1049)	Placebo (n=1056)	p Value	Mean difference	CI for the difference
*Coronary catheterisations that led to PTCA ad hoc are listed under interventions.
CABG, coronary artery bypass graft; CCU, cardiac care unit; CI, confidence interval; ICU, intensive care unit; PTCA, percutaneous transluminal coronary angioplasty.
Hospital admissions (days)
ICU/CCU	0.67	0.76	NS	−0.09	−0.28 to 0.10
Cardiology/medical ward	2.39	2.23	NS	0.16	−0.29 to 0.61
Thoracic surgery ICU	0.18	0.17	NS	0.01	−0.06 to 0.08
Thoracic surgery ward	0.57	0.58	NS	−0.01	−0.20 to 0.18
Other wards	0.47	0.47	NS	0.00	−0.22 to 0.22
All admissions	4.28	4.21	NS	0.07	−0.69 to 0.83

Investigations
Exercise test	0.86	0.90	0.03	−0.04	−0.08 to 0.00
Echocardiogram	0.05	0.05	NS	0.00	−0.02 to 0.02
Coronary catheterisation*	0.13	0.15	NS	−0.02	−0.05 to 0.01

Interventions
PTCA without stent	0.03	0.03	NS	0.00	−0.01 to 0.01
PTCA with stent	0.04	0.05	NS	−0.01	−0.03 to 0.01
CABG	0.06	0.06	NS	0.00	−0.02 to 0.02

Pharmaceuticals (treatment episodes)
Streptokinase	0.004 (4)	0.010 (10)	NS	−0.006	−0.013 to 0.001
Alteplase	0.005 (5)	0.012 (13)	NS	−0.007	−0.016 to 0002
Reteplase	0.001 (1)	0.001 (1)	NS	0.000	−0.002 to 0.002
Abciximab	0.006 (6)	0.005 (5)	NS	0.001	−0.005 to 0 007

Intervention treatment
Dalteparin (10 000 IU per day)/placebo	79.3	81.6	NS	−2.3	−4.6 to 0.0
Dalteparin (15 000 IU per day)/placebo	75.8	80.2	0.024	−4.4	−8.1 to −0.7

Outpatient care
Visits to physician	3.66	3.63	NS	0.03	−0.10 to 0.16
Visits to nurse	0.85	0.91	NS	−0.06	−0.21 to 0.09
Visits to physiotherapist	0.64	0.70	NS	−0.06	−0.27 to 0.15
Physician home visits	0.06	0.05	NS	0.01	−0.02 to 0.04
Nurse home visits	0.18	0.36	NS	−0.18	−0.46 to 0.10